Crizotinib: ALK & ROS1 Inhibitor for Lung Cancer
Crizotinib is an antineoplastic agent belonging to the class of tyrosine kinase inhibitors. It specifically inhibits the activity of ALK (Anaplastic Lymphoma Kinase) and ROS1 receptors. In patients harboring genetic mutations in these genes, Crizotinib halts cancer cell proliferation and induces apoptosis.
This is a targeted therapy designed to attack tumor cells specifically while minimizing damage to healthy tissues. On Unifarm, you can find a list of medications containing this active ingredient for lung cancer treatment.
Indications
- ALK-positive Non-Small Cell Lung Cancer (NSCLC): Advanced or metastatic stage in adults.
- ROS1-positive Non-Small Cell Lung Cancer: Advanced stage disease.
- Therapy is initiated only after ALK or ROS1 mutations are confirmed via genetic testing.
Dosage and administration
Crizotinib is taken orally as capsules. Food intake does not affect absorption. Capsules must be swallowed whole, without chewing or opening.
Standard Regimen:
- Recommended dose: 250 mg twice daily.
- It is advisable to take the medication at the same time each morning and evening.
- If a dose is missed, it should be taken as soon as remembered unless the next dose is due within 6 hours.
A physician may reduce the dosage if severe side effects occur.
- Hypersensitivity to Crizotinib.
- Severe hepatic or renal impairment (requires dose adjustment).
- Congenital Long QT Syndrome.
- Pregnancy and breastfeeding (high risk of fetal harm).
- Children (safety and efficacy for NSCLC not established).
A distinct feature of this drug is its effect on vision. Common reactions include:
- Vision: Visual disturbances such as light flashes, trails, or diplopia (usually mild and transient).
- Gastrointestinal: Nausea, diarrhea, vomiting, constipation.
- Cardiac: Bradycardia (slow heart rate), QT interval prolongation on ECG.
- Hepatic: Elevated liver enzymes (ALT, AST).
- Edema: Peripheral swelling of hands and feet.
